In silico Evaluation of a Vancomycin Dosing Guideline Among Adults with Serious Infections

Author:

Williams Paul12ORCID,Cotta Menino Osbert13,Abdul-Aziz Mohd H.13,Wilks Kathryn45,Farkas Andras67,Roberts Jason A.138910

Affiliation:

1. University of Queensland Centre for Clinical Research (UQCCR), Faculty of Medicine, The University of Queensland, Brisbane, Queensland, Australia;

2. Pharmacy Department, Sunshine Coast University Hospital, Birtinya, Queensland, Australia;

3. Herston Infectious Diseases Institute (HeIDI), Metro North Health, Brisbane, Australia;

4. Infectious Diseases Department, Sunshine Coast University Hospital, Birtinya, Queensland, Australia;

5. School of Public Health, The University of Queensland, Brisbane, Queensland, Australia

6. Department of Pharmacy, Mount Sinai West, New York, New York;

7. Optimum Dosing Strategies, Bloomingdale, New Jersey

8. Department of Intensive Care Medicine, Royal Brisbane and Women's Hospital, Brisbane, Queensland, Australia;

9. Pharmacy Department, Royal Brisbane and Women's Hospital, Brisbane, Queensland, Australia; and

10. Division of Anaesthesiology Critical Care Emergency and Pain Medicine, Nîmes University Hospital, University of Montpellier, Nîmes France.

Abstract

Background: This study aimed to compare the achievement of pharmacokinetic–pharmacodynamic (PK-PD) exposure targets for vancomycin using a newly developed dosing guideline with product-information-based dosing in the treatment of adult patients with serious infections. Methods: In silico product-information- and guideline-based dosing simulations for vancomycin were performed across a range of doses and patient characteristics, including body weight, age, and renal function at 36–48 and 96 hours, using a pharmacokinetic model derived from a seriously ill patient population. The median simulated concentration and area under the 24-hour concentration–time curve (AUC0-24) were used to measure predefined therapeutic, subtherapeutic, and toxicity PK-PD targets. Results: Ninety-six dosing simulations were performed. The pooled median trough concentration target with guideline-based dosing at 36 and 96 hours was achieved in 27.1% (13/48) and 8.3% (7/48) of simulations, respectively. The pooled median AUC0-24/minimum inhibitory concentration ratio with guideline-based dosing at 48 and 96 hours was attained in 39.6% (19/48) and 27.1% (13/48) of simulations, respectively. Guideline-based dosing simulations yielded improved trough target attainment compared with product-information-based dosing at 36 hours and significantly less subtherapeutic drug exposure. The toxicity threshold was exceeded in 52.1% (25/48) and 0% (0/48) for guideline- and product-information-information-based dosing, respectively (P < 0.001). Conclusions: A Critical care vancomycin dosing guideline appeared slightly more effective than standard dosing, as per product information, in achieving PK-PD exposure associated with an increased likelihood of effectiveness. In addition, this guideline significantly reduced the risk of subtherapeutic exposure. The risk of exceeding toxicity thresholds, however, was greater with the guideline, and further investigation is suggested to improve dosing accuracy and sensitivity.

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Pharmacology (medical),Pharmacology

Cited by 1 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3